Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria

Leuk Lymphoma. 2016 May;57(5):1191-3. doi: 10.3109/10428194.2015.1096356. Epub 2015 Oct 20.

Authors

Armin Rashidi¹, Eunhye Oak¹, Kenneth R Carson¹, Nina D Wagner-Johnston¹, Friederike Kreisel², Nancy L Bartlett¹

Affiliations

¹ a Division of Oncology , Washington University School of Medicine , St. Louis , MO , USA ;
² b Department of Pathology and Immunology , Washington University School of Medicine , St. Louis , MO , USA.

PMID: 26397936
DOI: 10.3109/10428194.2015.1096356

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Murine-Derived / adverse effects
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
Doxorubicin / adverse effects
Doxorubicin / therapeutic use
Humans
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / mortality
Prednisone / adverse effects
Prednisone / therapeutic use
Rituximab
Treatment Outcome
Vincristine / adverse effects
Vincristine / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone